| Bioactivity | Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits DPD, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil)[1][2]. | ||||||||||||
| Target | Dihydropyrimidine dehydrogenase. | ||||||||||||
| In Vivo | Eniluracil (5-Ethynyluracil) (1 mg/kg; i.p.; single daily for 3 days) exhibits neither toxicity nor intrinsic antitumor activity, and greatly improves FUra (5-fluorouracil) therapy in rats[1]. Animal Model: | ||||||||||||
| Name | Eniluracil | ||||||||||||
| CAS | 59989-18-3 | ||||||||||||
| Formula | C6H4N2O2 | ||||||||||||
| Molar Mass | 136.11 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Cao S, et al. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res. 1994 Mar 15;54(6):1507-10. [2]. Schilsky RL, et al. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49. |
Eniluracil
CAS: 59989-18-3 F: C6H4N2O2 W: 136.11
Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibl
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.